Sunday 18 October 2026
Export NRXP’s income statement to Excel — free account
NRx Pharmaceuticals, Inc.
NRXP Healthcare Biotechnology
NRx Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million. In the quarter to June 2026, EPS grew 55.1% and free cash flow fell 142.6%, each against the same quarter a year earlier.
2.60
0.11
−4.06%
Follow NRXP
NRx Pharmaceuticals, Inc. (NRXP) P/E ratio
NRx Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 409× (March 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 409×
Ten-year median
0.0×
Current reading's percentile
80
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NRXP NRx Pharmaceuticals, Inc. | n/m |
| ENGN enGene Therapeutics Inc compare | n/m |
| ARMP Armata Pharmaceuticals, Inc. compare | n/m |
| SPRB Spruce Biosciences, Inc. compare | n/m |
| SEER Seer, Inc. compare | n/m |
| OTLK Outlook Therapeutics, Inc. compare | n/m |
| ABOS Acumen Pharmaceuticals, Inc. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)